Tuberculosis (TB) is the most deadly infectious disease in existence， and the only available vaccine， (BCG)， is almost a century old and poorly protective. The immunological complexity of TB， coupled with rising resistance to antimicrobial therapies， necessitates a pipeline of diverse novel vaccines. Here， we show that spores can be coated with a fusion protein 1 ("FP1") consisting of (Mtb) antigens Ag85B， ACR， and HBHA. The resultant vaccine， Spore-FP1， was tested in a murine low-dose Mtb aerosol challenge model. Mice were primed with subcutaneous BCG， followed by mucosal booster immunizations with Spore-FP1. We show that Spore-FP1 enhanced pulmonary control of Mtb， as evidenced by reduced bacterial burdens in the lungs. This was associated with elevated antigen-specific IgG and IgA titers in the serum and lung mucosal surface， respectively. Spore-FP1 immunization generated superior antigen-specific memory T-cell proliferation in both CD4 and CD8 compartments， alongside bolstered Th1-， Th17-， and Treg-type cytokine production， compared to BCG immunization alone. CD69CD103 tissue resident memory T-cells (Trm) were found within the lung parenchyma after mucosal immunization with Spore-FP1， confirming the advantages of mucosal delivery. Our data show that Spore-FP1 is a promising new TB vaccine that can successfully augment protection and immunogenicity in BCG-primed animals.